期刊文献+

120例肝硬化失代偿期患者并发低钠血症临床分析

暂未订购
导出
摘要 目的探讨肝硬化失代偿期患者并发低钠血症的临床特点。方法回顾性分析2008年1月至2009年6月本院消化内科120例肝硬化失代偿期合并低钠血症患者的临床资料。结果低钠血症发生程度随肝功能分级不同而有显著性差异,且其程度与肝性脑病、肝肾综合征及预后显著相关。结论肝硬化失代偿期患者低钠血症是预测预后的重要指标,其程度能提供一定的评估病情及预后依据。 Objective To explore the clinical characteristics of decompensated cirrhosis complicated with hyponatremia. Methods Clinical data of 120 cases with ecompensated cirrhosis complicated with hyponatremia were retrospectively studied. Results The degree of hyponatremia varies significantly according to the different degree of liver function, and it is related to hepatic encephalopathy, hepatorenal syndrome and the prognosis. Conclusions Cirrhosis complicated with hyponatremia is an important index for'predicting the prognosis, its severity provides evidence for evaluation and predicting the prognosis.
出处 《浙江临床医学》 2010年第5期468-469,共2页 Zhejiang Clinical Medical Journal
关键词 肝硬化 低钠血症 肝性脑病 肝肾综合征 Liver cirrhosis- Hyponatremia Hepatic encephalopathy Hepatorenal syndrome
  • 相关文献

参考文献8

  • 1中华医学会传染病与,寄生虫病学分会,肝病学分会.病毒性肝炎防治方案[J].中华肝脏病杂志,2000,8(6):324-329. 被引量:14017
  • 2叶任高 主编.内科学 第五版[M].北京:人民卫生出版社,2000.732.
  • 3徐晓光,蔡洪培.肝硬化低钠血症研究进展[J].中华消化杂志,2002,22(9):560-562. 被引量:95
  • 4Jalan R,Hayesp C.Sodium handling in patients with Compensated cirrhosis is dependent on the severity of liver disease and portal Pressure.Gut,2000,46:527-533.
  • 5陈灏珠 主编.实用内科学 第11版[M].北京:人民卫生出版社,2001.1652.
  • 6Gulbergv M,Mouers H,Henriksen JH,et al.increased renal production of C-type nateiuretic peptide(CNP) in patients with cirrhosis and functional renal failure.Gut,2000,47:852-657.
  • 7韦炜.肝硬化失代偿期并发低钠血症的治疗[J].中国临床保健杂志,2006,9(1):70-71. 被引量:7
  • 8Borroni G.Clinical relevance of hypoafraemia for the hospital outcome of cirrhotic patients.Digliver Dis,2000,32:605-610.

二级参考文献13

  • 1Decaux G.Difference is solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985[].Journal of Laboratory and Clinical Medicine.2001
  • 2Gadano A,Moreau R,Pessione F,et al.Aquaretic effects of niravoline, a kappa-opioid agonist, in patients with cirrhosis[].Journal of Hepatology.2000
  • 3Gines P,Jimenez W.Aquaretic agent: a new potential treatment of dilutional hyponatremia in cirrhosis[].Journal of Hepatology.1996
  • 4Gines P,Jimenez W.Aquaretic agents: a new potential treatment of dilutional hyponatremia in cirrhosis[].Journal of Hepatology.1996
  • 5Bosch-Marce M,Jimenez W,Angeli P,et al.Aquaretic effect of the kappa-opioid agonist RU 51599 in cirrhotic rats with ascites and water retention[].Gastroenterology.1995
  • 6Bosch-Marce M,Poo JL,Jimenez W,et al.Comparison of two aquaretic drugs (niravoline and OPC-31260) in cirrhotic rats with ascites and water retention[].Journal of Pharmacology and Experimental Therapeutics.1999
  • 7Borroni G,Maggi A,Sangiovanni A,et al.Clinical relevance of hyponatraemia for the hospital outcome of cirrhotic patients[].Digestive and Liver Disease.2000
  • 8Serradeil-Le-Gal C.Nonpeptide antagonists for vasopressin receptors.Pharmacology of SR 121463A, a new potent and highly selective V2 receptor antagonist[].Advances in Experimental Medicine and Biology.1998
  • 9Yamamura Y,Ogawa H,Yamashita H,et al.Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist[].British Journal of Pharmacology.1992
  • 10Gulberg V,Moller S,Henriksen JH,et al.Increased renal production of C-type natriuretic peptide (CNP) in patients with cirrhosis and functional renal failure[].Gut.2000

共引文献14203

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部